Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
Amazon is discontinuing its Amazon One biometric palm payment system in 2026, ending a nearly six-year experiment in contactless retail technology that faced scrutiny over data security.
As the wearables market surges, Biolinq CEO Richard Yang positions smart patches as the next evolution, capable of tracking deep biochemical data where watches track surface metrics, with his company's FDA-cleared glucose sensor leading the charge.
Apple's acquisition of Israeli AI audio startup Q.ai signals a deeper push into biometric wearables, as the tech giant reportedly reshuffles its 2026 roadmap to prioritize premium iPhones—including a long-rumored foldable model—while navigating ongoing component shortages.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.
Amidst a cautious market climate, companies with substantial insider ownership often signal strong internal conviction. We examine three such firms—spanning South Korean tourism, Chinese sensors, and Taiwanese biopharma—where executives and directors have significant skin in the game.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
